Title: Mammalian Host Cell Modified by RNAi to Inhibit Alpha 1,6-Fucosyltransferase
Filed: Nov. 28, 2005
Lead Inventor: Yutaka Kanda, Kyowa Hakko Kogyo
The invention, the patent’s abstract states, “relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent, cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition, and use thereof.”
Title: Compositions and Methods for siRNA Inhibition of Angiogenesis
Filed: June 12, 2007
Inventor: Sam Reich, Opko Health
The patent application, its abstract states, claims “embodiments of methods of using siRNAs targeting VEGF … to stabilize visual acuity in a subject, to inhibit choroidal neovascularization lesions, to treat age-related macular degeneration, to treat diabetic macular edema, and to decrease foveal thickness in subjects. … Additionally, methods of treating age-related macular degeneration and diabetic macular edema by administering combinatorial therapy comprising an siRNA targeting VEGF and a non-siRNA VEGF antagonist are described.”
Title: Double-Stranded and Single-Stranded RNA Molecules with 5’ Triphosphates and Their Use for Inducing Interferon
Filed: Sept. 21, 2007
Lead Inventor: John Rossi, City of Hope
The patent application, according to its abstract, claims “double-stranded and single-stranded RNA molecules, and their use in methods for inducing interferon. … The interferon induction provides anti-viral and other medically useful effects, such as anti-cancer effects. Also provided are methods for reducing or inhibiting interferon induction exhibited by such molecules, particularly siRNA and shRNA molecules produced in vitro.”
Title: Method of Delivering RNA Interference and Uses Thereof
Filed: Aug. 15, 2005 PCT Filed: Aug. 15, 2005
Lead Inventor: Judy Lieberman, Immune Disease Institute (Harvard Medical School)
“The invention provides a method of RNA interference, which comprises contacting the cell with a fusion protein/double-stranded RNA complex,” the patent application’s abstract states. The complex containing the double-stranded RNA segment also contains a fusion protein, which itself comprises a targeting moiety that “specifically binds to a site on a target cell,” as well as a binding moiety that will bind to the dsRNA, which triggers RNAi, the abstract adds.
Title: Treatment of Neurological Disorders by dsRNA Administration
Filed: July 17, 2007
Lead Inventor: Gabriele Dorn, Novartis
The invention relates to “methods to treat neurological disorders comprising intrathecal injection of an effective amount of a double-stranded RNA into a subject in need, wherein the dsRNA inhibits the expression of a target gene and to pharmaceutical compositions useful for such treatment.”
Title: Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases
Filed: Aug. 20, 2007
Lead Inventor: Yijia Liu, Sirnaomics
The patent application, its abstract states, claims “compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control [neovascularization] through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological [neovascularization] tissues.
“Tissue-targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference” are also claims, the abstract adds. “The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of [neovascularization] diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.”
Title: System and Methods for Short RNA Expression
Filed: Jan. 21, 2005 PCT Filed: Jan. 21, 2005
Lead Inventor: Philipp Oberdoerffer, Immune Disease Institute
“The invention provides inducible expression systems for making short RNA transcripts that can be used in cells and transgenic animals for a variety of applications, including, but not limited to, producing and studying the effects of RNAi- and microRNA-mediated gene silencing,” the patent application’s abstract states.
Title: Oligonucleotides for RNA Interference and Biological Applications Thereof
Filed: June 1, 2006 PCT Filed: June 1, 2006
Lead Inventor: Jean-Paul Behr, Universite Louis Pasteur
According to the patent application’s abstract, “the invention relates to compositions comprising double-stranded oligonucleotides of identical or different sequences and/or length,” and having specific sequences.
“Compositions of transfection comprising said oligonucleotide compositions and there used for [therapeutic] application,” are also claimed, the abstract adds.
Title: Polyconjugates for In Vivo Delivery of Polynucleotides
Filed: Aug. 17, 2007
Lead Inventor: David Rozema, Mirus Bio
The invention “is directed to compounds, compositions, and methods useful for delivering polynucleotides or other cell-impermeable molecules to mammalian cells,” the patent application’s abstract states. Among these are “polyconjugate systems that incorporate targeting, anti-opsonization, anti-aggregation, and transfection activities into small biocompatible in vivo delivery vehicles. The use of multiple reversible linkages connecting component parts provides for physiologically responsive activity modulation.”